Lacosamide for the treatment of partial-onset seizures

References

• Jacoby A, Baker GA. Quality-of-life trajectories in epilepsy: a review of the literature. Epilepsy Behav. 12(4), 557–571 (2008).
   PubMed Web of Science ®Google Scholar
• Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 52(5), 949–956 (2011).
   PubMed Web of Science ®Google Scholar
• Meador KJ, French J, Loring DW, Pennell PB. Disparities in NIH funding for epilepsy research. Neurology 77(13), 1305–1307 (2011).
   PubMedGoogle Scholar
• Neligan A, Bell GS, Johnson AL, Goodridge DM, Shorvon SD, Sander JW. The long-term risk of premature mortality in people with epilepsy. Brain 134(Pt 2), 388–395 (2011).
   PubMed Web of Science ®Google Scholar
• Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 51(11), 2241–2246 (2010).
   PubMedGoogle Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 9(7), 464–468 (2000).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 66(14), 1817–1829 (2006).
   PubMed Web of Science ®Google Scholar
• The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guidance 137 (2012).
   Google Scholar
• French JA, Kanner AM, Bautista J et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62(8), 1252–1260 (2004).
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47(7), 1094–1120 (2006).
   PubMed Web of Science ®Google Scholar
• VIMPAT® (lacosamide) Prescribing Information. UCB, Inc., Smyrna, GA, USA (2011).
   Google Scholar
• VIMPAT® (lacosamide) Summary of Product Characteristics for Lacosamide. UCB Pharma, S.A., Belgium (2011).
   Google Scholar
• Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13(1), 21–42 (2007).
   PubMedGoogle Scholar
• Choi D, Stables JP, Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 39(9), 1907–1916 (1996).
   PubMed Web of Science ®Google Scholar
• Park KD, Morieux P, Salomé C et al. Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J. Med. Chem. 52(21), 6897–6911 (2009).
   PubMedGoogle Scholar
• Wang Y, Brittain JM, Jarecki BW et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J. Biol. Chem. 285(33), 25296–25307 (2010).
   PubMedGoogle Scholar
• Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73(1), 157–169 (2008).
   PubMed Web of Science ®Google Scholar
• Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 326(1), 89–99 (2008).
   PubMed Web of Science ®Google Scholar
• Wolff C, Carrington B, Varrin-Doyer M et al. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). CNS Neurosci. Ther. (2011) (In Press).
   Google Scholar
• Wang Y, Brittain JM, Wilson SM, Khanna R. Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun. Integr. Biol. 3(2), 172–175 (2010).
   PubMedGoogle Scholar
• Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol. Neurobiol. 43(3), 180–191 (2011).
   PubMed Web of Science ®Google Scholar
• Stöhr T, Kupferberg HJ, Stables JP et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74(2–3), 147–154 (2007).
   PubMed Web of Science ®Google Scholar
• Biton V. Lacosamide for the treatment of diabetic neuropathic pain. Expert Rev. Neurother. 8(11), 1649–1660 (2008).
   PubMedGoogle Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48(7), 1308–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V et al.; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51(6), 958–967 (2010).
   PubMed Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 50(3), 443–453 (2009).
   PubMed Web of Science ®Google Scholar
• Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J. Clin. Pharmacol. doi:10.1177/0091270011426875 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J. Clin. Pharmacol. 50(4), 459–471 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Low potential for drug drug interaction of lacosamide. Epilepsia 48, 104 (2007).
   Web of Science ®Google Scholar
• Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three Phase II/III clinical trials. CNS Drugs 24(12), 1041–1054 (2010).
   PubMed Web of Science ®Google Scholar
• Doty P, Biton V, Fountain NB et al. Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials. Neurology 72, A225 (2009).
   Google Scholar
• Cramer J, Borghs S, De Backer M, Doty P. Improved seizure severity, health-realted quality of life and health status reported by patients during long-term treatment with locasimide: analysis of pooled open-label data. Presented at: The 65th Annual Meeting of the American Epilepsy Society. Baltimore, MD, USA, 6–11 December 2011.
   Google Scholar
• De La Loge C, Borghs S, Eggert-Formella A, Cramer J, Mueller K, Doty P. Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSQ, and PGIC data from three phase II/III clinical trials. Neurology 74(Suppl. 2) (2010).
   Google Scholar
• Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24(12), 1055–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 53(3), 521–528 (2012).
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Fountain NB, Kaubrys G et al. Lacosamide: long-term safety and efficacy in partial-onset seizures. Presented at: The 29th International Epilepsy Congress. Rome, Italy, 28 August–1 September 2011.
   Google Scholar
• Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, Doty P. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August–1 September 2011.
   Google Scholar
• Isojarvi J, Rosenow F, Faught E, Hebert D, Doty P. Lacosamide efficacy in partial-onset seizures with and without secondary generalization: a pooled analysis of three Phase II/III trials. Neurology 74(Suppl. 2) (2010).
   Google Scholar
• Brodie MJ, Covanis A, Gil-Nagel A et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 21(4), 331–341 (2011).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Sills GJ. Combining antiepileptic drugs–rational polytherapy? Seizure 20(5), 369–375 (2011).
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 98(2–3), 194–198 (2012).
   PubMed Web of Science ®Google Scholar
• Hillenbrand B, Wisniewski I, Jürges U, Steinhoff BJ. Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events. Epilepsy Behav. 22(3), 548–551 (2011).
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Epilepsy Behav. 22(3), 499–504 (2011).
   PubMedGoogle Scholar
• Villaneuva V, López-Gamariz E, López-Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 23, 298–304 (2012).
   PubMedGoogle Scholar
• Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39(1), 81–88 (1998).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Baker GA, Jacoby A. Development of a new seizure severity questionnaire: initial reliability and validity testing. Epilepsy Res. 48(3), 187–197 (2002).
   PubMedGoogle Scholar
• Krauss G, Ben-Menachem E, Mameniskiene R et al.; SP757 Study Group. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 51(6), 951–957 (2010).
   PubMed Web of Science ®Google Scholar
• Chen LL, Haneef Z, Dorsch A, Keselman I, Stern JM. Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure 20(3), 263–265 (2011).
   PubMedGoogle Scholar
• Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 14(2), 429–431 (2009).
   PubMed Web of Science ®Google Scholar
• Turpín-Fenoll L, Millán-Pascual J, Navarro-Muñoz S, del Saz-Saucedo P, Rueda-Medina I. [The use of oral lacosamide in a patient with refractory partial epileptic status]. Rev. Neurol. 50(10), 603–606 (2010).
   PubMedGoogle Scholar
• Albers JM, Möddel G, Dittrich R et al. Intravenous lacosamide – an effective add - on treatment of refractory status epilepticus. Seizure 20(5), 428–430 (2011).
   PubMedGoogle Scholar
• Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit. Care 14(3), 348–353 (2011).
   PubMed Web of Science ®Google Scholar
• Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 52(10), e148–e152 (2011).
   Google Scholar
• Kellinghaus C, Berning S, Immisch I et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol. Scand. 123(2), 137–141 (2011).
   PubMed Web of Science ®Google Scholar
• Koubeissi MZ, Mayor CL, Estephan B, Rashid S, Azar NJ. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol. Scand. 123(2), 142–146 (2011).
   PubMed Web of Science ®Google Scholar
• Parkerson KA, Reinsberger C, Chou SH, Dworetzky BA, Lee JW. Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients. Epilepsy Behav. 20(1), 48–51 (2011).
   PubMed Web of Science ®Google Scholar
• Rantsch K, Walter U, Wittstock M, Benecke R, Rösche J. Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure 20(7), 529–532 (2011).
   PubMed Web of Science ®Google Scholar
• Fernandez EM, Franck AJ. Lacosamide for the treatment of refractory status epilepticus. Ann. Pharmacother. 45(11), 1445–1449 (2011).
   PubMedGoogle Scholar
• Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 18(3), 322–324 (2010).
   PubMed Web of Science ®Google Scholar
• Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 20(4), 725–727 (2011).
   PubMed Web of Science ®Google Scholar
• Nizam A, Mylavarapu K, Thomas D et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 52(10), e153–e155 (2011).
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Husain A, Rosenow F, McShea C, Isojarvi J, Doty P. Evaluation of long-term treatment with lacosamide for partial-onset seizures: a pooled analysis of open-label extension trials. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August–1 September 2011.
   Google Scholar
• LeRoy RF, Krauss G, Fountain NB, Dilley D, D’Cruz N, Doty P. Lacosamide: long-term safety in partial onset seizures. Presented at: 29th International Epilepsy Congress. Rome, Italy, 28 August–1 September 2011.
   Google Scholar
• Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49(3), 418–424 (2008).
   PubMed Web of Science ®Google Scholar
• Fountain N, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd G. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in patients with partial-onset seizures. Epilepsia 51(Suppl. 4), 123, abs p416 (2010).
   Google Scholar
• Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 20(1), 20–23 (2011).
   PubMed Web of Science ®Google Scholar
• Marik PE, Varon J. The management of status epilepticus. Chest 126(2), 582–591 (2004).
   PubMed Web of Science ®Google Scholar
• Lowenstein DH, Alldredge BK. Status epilepticus. N. Engl. J. Med. 338(14), 970–976 (1998).
   PubMed Web of Science ®Google Scholar
• Shorvon S, Baulac M, Cross H, Trinka E, Walker M; TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 49(7), 1277–1285 (2008).
   PubMed Web of Science ®Google Scholar
• Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav. 20(4), 691–693 (2011).
   PubMed Web of Science ®Google Scholar
• Guilhoto LM, Loddenkemper T, Gooty VD et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr. Neurol. 44(6), 414–419 (2011).
   PubMed Web of Science ®Google Scholar
• Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur. J. Paediatr. Neurol. 16(1), 15–19 (2012).
   PubMed Web of Science ®Google Scholar
• Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure 20(7), 586–588 (2011).
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 19, 650–655 (2010).
   PubMed Web of Science ®Google Scholar